InhalPlus
Developer of a patented non‑invasive bypass system for aerosol drug delivery that prevents dilution in ventilation circuits to enable high‑concentration pulmonary delivery during respiratory support. Focus areas include neonatal respiratory care (preterm infants with BPD), surfactant delivery, and aerosol therapy during adult respiratory support. Activities described include prototype refinement, clinical proof‑of‑concept studies, regulatory preparation for CE clinical studies, and partnerships with research hospitals and development organizations.
Industries
Nr. of Employees
small (1-50)
Products
Bypass aerosol delivery system for respiratory support
A non‑invasive device system that bypasses ventilation circuit dilution to deliver concentrated aerosols directly to patient airways during CPAP or mechanical ventilation.
InhalPlus
An innovative inhalation therapy system featuring patented bypass technology to prevent ventilation circuit dilution and enable effective, non-invasive delivery of highly concentrated aerosols under respiratory support for preterm infants and adults.
Bypass aerosol delivery system for respiratory support
A non‑invasive device system that bypasses ventilation circuit dilution to deliver concentrated aerosols directly to patient airways during CPAP or mechanical ventilation.
InhalPlus
An innovative inhalation therapy system featuring patented bypass technology to prevent ventilation circuit dilution and enable effective, non-invasive delivery of highly concentrated aerosols under respiratory support for preterm infants and adults.
Services
Iterative prototype development with usability testing alongside nursing staff and neonatologists at development partners.
Collaborative clinical studies executed with academic hospitals to validate in‑use efficiency and lung deposition under respiratory support.
Preparation of regulatory documentation and processes required for CE clinical study submissions and device classification pathways.
Iterative prototype development with usability testing alongside nursing staff and neonatologists at development partners.
Collaborative clinical studies executed with academic hospitals to validate in‑use efficiency and lung deposition under respiratory support.
Preparation of regulatory documentation and processes required for CE clinical study submissions and device classification pathways.
Expertise Areas
- Inhalation therapy device development
- Neonatal respiratory care
- Aerosol science
- Clinical trial planning and execution
Key Technologies
- Bypass aerosol delivery for ventilator circuits
- Mesh nebulizer compatibility
- Ventilator integration for continuous support
- Non‑invasive surfactant aerosol delivery
News & Updates
Announcement of €2.8M in non‑dilutive grants: €1.5M from EXIST to support prototype refinement and regulatory preparation, and €1.3M from IBT Lower Saxony to fund a clinical proof‑of‑concept study with clinical partners.
Secured separate grants totalling €2.8M to fund prototype refinement, usability work, regulatory preparation and a clinical proof‑of‑concept study with academic partners.
Announcement of €2.8M in non‑dilutive grants: €1.5M from EXIST to support prototype refinement and regulatory preparation, and €1.3M from IBT Lower Saxony to fund a clinical proof‑of‑concept study with clinical partners.
Secured separate grants totalling €2.8M to fund prototype refinement, usability work, regulatory preparation and a clinical proof‑of‑concept study with academic partners.